Tyra Biosciences CMO granted RSUs and options

Tyra Biosciences, Inc. reported that Chief Medical Officer Douglas J. Warner received new equity awards as part of his compensation.

Rhea-AI Filing Summary

Tyra Biosciences, Inc. reported that Chief Medical Officer Douglas J. Warner received new equity awards as part of his compensation. He was granted 25,000 restricted stock units (RSUs), each representing one share of common stock, with one quarter vesting on each of the first four anniversaries of May 5, 2026, subject to his continuous service. He also received a stock option for 85,000 shares of common stock at an exercise price of $33.93 per share, vesting in equal monthly installments over 48 months following May 5, 2026, also conditioned on continued service. These are grants and not open‑market purchases or sales.

Insider Trade Summary

Grant/Award: 110,000 shares

Grant/Award 2 txns

Insider Warner Douglas J

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	85,000	$0.00	$0.00
Grant/Award	Common Stock	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 85,000 contracts (Direct); Common Stock — 25,000 shares (Direct)

Footnotes (3)

1. F1. Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
2. F2. Includes RSUs.
3. F3. 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

RSU grant size: 25,000 RSUs Option grant size: 85,000 options Option exercise price: $33.93 per share +3 more

6 metrics

RSU grant size 25,000 RSUs Granted to CMO on May 5, 2026; vests over four years

Option grant size 85,000 options Stock Option (Right to Buy) granted May 5, 2026

Option exercise price $33.93 per share Exercise price for 85,000-share stock option

RSUs after grant 25,000 shares Total common shares underlying RSUs following transaction

Options after grant 85,000 options Total stock options held following transaction

Option expiration May 4, 2036 Expiration date of 85,000-share stock option

Key Terms

restricted stock units, RSUs, Stock Option (Right to Buy), vesting commencement date, +1 more

5 terms

restricted stock units financial

"Represents restricted stock units ("RSUs") granted on May 5, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Each RSU represents a contingent right to receive one share of common stock"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vesting commencement date financial

"the vesting commencement date, subject to the Reporting Person's continuous service"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

continuous service financial

"subject to the Reporting Person's continuous service through each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tyra Biosciences (TYRA) report for Douglas J. Warner?

Tyra Biosciences reported that Chief Medical Officer Douglas J. Warner received equity grants. He was awarded 25,000 restricted stock units and a stock option for 85,000 shares, both granted on May 5, 2026, as part of his compensation package.

How many RSUs did the Tyra Biosciences (TYRA) CMO receive in this Form 4?

Douglas J. Warner received 25,000 restricted stock units. One quarter of these RSUs vest on each of the first four anniversaries of May 5, 2026, provided he remains in continuous service with Tyra Biosciences through each vesting date.

What are the terms of the 85,000-share stock option granted by Tyra Biosciences (TYRA)?

The stock option covers 85,000 shares of Tyra Biosciences common stock at a $33.93 exercise price. One forty-eighth of the option vests monthly after May 5, 2026, contingent on Douglas J. Warner’s continuous service to the company through each vesting date.

Are the Tyra Biosciences (TYRA) insider grants open-market purchases or compensation awards?

The transactions are compensation-related awards, not open-market trades. Both the 25,000 restricted stock units and the 85,000-share stock option were granted at no cash cost to Douglas J. Warner as part of his role as Chief Medical Officer.

When do Douglas J. Warner’s Tyra Biosciences (TYRA) RSUs and options start vesting?

Both awards use May 5, 2026 as the vesting commencement date. The RSUs vest annually over four years, while the stock option vests in equal monthly installments over 48 months, subject in each case to continuous service with Tyra Biosciences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warner Douglas J

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		A		25,000(1)	A	$0	25,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$33.93	05/05/2026		A		85,000		(3)	05/04/2036	Common Stock	85,000	$0	85,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

2. Includes RSUs.

3. 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Ali D. Fawaz, Attorney-in-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)